No significant protective effect was shown by another study investigating candesartan adjuvant therapy in HER2+ breast cancer patients receiving trastuzumab, although candesartan treatment was not started until 3 months after anthracycline treatment [106]. This evidence concerns the gene ERBB2 and breast cancer.